Article
Multidisciplinary Sciences
K. C. Nicolaou, Stephan Rigol, Emmanuel N. Pitsinos, Dipendu Das, Yong Lu, Subhrajit Rout, Alexander W. Schammel, Dane Holte, Baiwei Lin, Christine Gu, Hetal Sarvaiya, Jose Trinidad, Nicole Barbour, Amanda M. Valdiosera, Joseph Sandoval, Christina Lee, Monette Aujay, Hanan Fernando, Anukriti Dhar, Holger Karsunky, Nicole Taylor, Marybeth Pysz, Julia Gavrilyuk
Summary: ADCs have shown strong efficacy as targeted anticancer therapeutics, particularly with enediyne DNA-damaging payloads such as uncialamycin, displaying high selectivity and cytotoxicity in vitro and in vivo.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Oncology
Hany E. Marei, Carlo Cenciarelli, Anwarul Hasan
Summary: The primary purpose of ADCs is to increase the efficacy of anticancer medications by minimizing systemic drug distribution and targeting specific cells. Current research focuses on combination trials due to the limited long-term benefits for patients. ADCs' interaction with tumors and their microenvironment has significant therapeutic consequences. Clinical trials are underway to explore the potential use of ADC therapy in various tumor types.
CANCER CELL INTERNATIONAL
(2022)
Review
Pharmacology & Pharmacy
Zhixia Zhou, Qianqian Cao, Yujing Diao, Yin Wang, Linhai Long, Shoushi Wang, Peifeng Li
Summary: In recent years, natural active substances from the marine environment have attracted great attention in the development of new antitumor drugs. Although a series of marine-derived compounds with potential antitumor effects have been discovered, their mechanisms of action are still not well understood. Emerging studies have found that noncoding RNAs (ncRNAs) play important roles in the antitumor mechanisms of marine-derived agents. This review summarizes the latest research progress on the regulation of ncRNAs associated with marine-derived agents in tumor cell proliferation, apoptosis, cell cycle, invasion, migration, drug sensitivity, and resistance. The review also discusses recent advances in marine food-derived ncRNAs as antitumor agents that modulate cross-species gene expression.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Youwen Zhu, Kun Liu, Kailing Wang, Hong Zhu
Summary: Different ADCs appear to have varying effects on treatment-related adverse events, providing comprehensive data for clinicians and patients on how to manage toxicities from ADCs in clinical practice.
Review
Chemistry, Medicinal
Ivan Cheng-Sanchez, Federico Moya-Utrera, Cristina Porras-Alcala, Juan M. Lopez-Romero, Francisco Sarabia
Summary: Antibody-drug conjugates (ADCs) are an important class of therapeutics for cancer treatment, combining the selective targeting properties of antibodies with the cytotoxicity of payload drugs to reduce off-target toxicities in patients, resulting in high specificity and potency.
Article
Chemistry, Multidisciplinary
Michele Anselmi, Adina Borbely, Eduard Figueras, Carmela Michalek, Isabell Kemker, Luca Gentilucci, Norbert Sewald
Summary: The study utilized a hydrophilic beta-glucuronidase-cleavable linker to connect an anticancer drug with a target protein, demonstrating the potential of hydrophilic sugar linkers in reducing cytotoxicity and providing guidance for the development of therapies containing hydrophobic anticancer drugs.
CHEMISTRY-A EUROPEAN JOURNAL
(2021)
Review
Pharmacology & Pharmacy
Zhijia Wang, Hanxuan Li, Lantu Gou, Wei Li, Yuxi Wang
Summary: Antibody-drug conjugates (ADCs) combine the advantages of monoclonal antibodies and drugs, showing great clinical potential. The payload of ADC drugs plays a crucial role in determining their efficacy, leading to significant research advancements and the development of novel efficient payloads with diverse targets and reduced side effects.
ACTA PHARMACEUTICA SINICA B
(2023)
Review
Oncology
Giampaolo Bianchini, Grazia Arpino, Laura Biganzoli, Sara Lonardi, Fabio Puglisi, Daniele Santini, Matteo Lambertini, Giovanni Pappagallo
Summary: This study discusses the effectiveness and side effects of antibody-drug conjugates (ADCs) in the treatment of solid tumors, with nausea and vomiting being the most common adverse reactions. The expert panels propose methods and recommendations for preventing and mitigating ADC-associated emesis, but further research and evidence are needed.
Article
Oncology
Sajad Yaghoubi, Tohid Gharibi, Mohammad Hossein Karimi, Muhammad Sadeqi Nezhad, Alexander Seifalian, Reza Tavakkol, Nader Bagheri, Asiyeh Dezhkam, Meghdad Abdollahpour-Alitappeh
Summary: The study successfully established an antibody drug conjugate using trastuzumab, which exhibited higher antitumor activity against HER2-positive breast cancer and showed potential for inhibiting colony formation in HER2-positive cells.
Review
Oncology
Panagiotis Filis, Ioannis Zerdes, Theodora Soumala, Alexios Matikas, Theodoros Foukakis
Summary: Antibody-drug conjugates (ADCs) have shown promising results in the treatment of solid tumors, with multiple clinical trials and approved drugs confirming their efficacy and safety.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Chemistry, Medicinal
Rong Huang, Yao Sheng, Zili Xu, Ding Wei, Xiaoling Song, Biao Jiang, Hongli Chen
Summary: The natural product combretastatin A4 (CA4) has been identified as a versatile new payload for antibody-drug conjugates (ADCs), showing high potency against cancer cells and significant antitumor activities in EGFR-positive xenograft models. This research suggests that CA4 is a viable option for ADCs research and development.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Chemistry, Medicinal
Vesela Kostova, Patrice Desos, Jerome-Benoit Starck, Andras Kotschy
Summary: ADC has emerged as an efficient therapeutic approach for various cancers, combining the selective targeting of tumor cells through antigen-directed recognition and potent cell-killing by cytotoxic payloads. The selection of appropriate antibody and drug payload is dictated by the pharmacology of the targeted disease, while there is more flexibility in choosing the conjugating linker. This paper reviews the chemistry of ADCs, focusing on methods that enable the efficient assembly of ADC from its three components and the controlled release of the drug payload.
Review
Chemistry, Multidisciplinary
Davinder Singh, Divya Dheer, Abhilash Samykutty, Ravi Shankar
Summary: ADCs, a rapidly growing class of biotherapeutics in oncology, are still in early stages of clinical application for gastrointestinal cancers with limited success. Research is being conducted to develop a new generation of ADCs against gastrointestinal cancers by improving key components and focusing on technical advancements.
JOURNAL OF CONTROLLED RELEASE
(2021)
Review
Oncology
Yingze Zhu, Miao Zhou, Wenyue Kong, Congling Li
Summary: Gastric cancer is one of the most common malignant tumors worldwide, but the efficacy of conventional treatments is limited. Antibody-drug conjugates (ADCs) have emerged as a promising approach for selective targeting of cancer cells. Clinical studies have shown promising results and significant progress in ADC-based therapies for gastric cancer. Currently, several ADCs targeting different receptors are being investigated in clinical trials for gastric cancer patients.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Yurou Chu, Xiangxiang Zhou, Xin Wang
Summary: ADCs are a promising class of immunotherapies with the potential to specifically target tumor cells and improve the therapeutic index of cytotoxic drugs. Three ADCs have been approved for lymphoma treatment, showing significant efficacy in recent years.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
